Immunoglobulin Or Antibody Binds A Drug, Hapten, Hapten-carrier Complex, Or Specifically Identified Chemical Structure (e.g., Theophylline, Digoxin, Etc.) Patents (Class 435/345)
-
Patent number: 11187706Abstract: Provided is a method of detecting the presence of an anti-Zika virus (ZIKV) antibody in a sample, including contacting a sample with a suspension having a plurality of microspheres wherein individual microspheres are conjugated to a peptide and the peptide includes a ZIKV peptide selected from the group including ZIKV NS1, ZIKV NS5, and ZIKV envelope protein, forming a first incubated suspension by incubating said sample with said suspension to permit binding of anti-ZIKV antibodies present in the sample to said microspheres, forming a second incubated suspension by contacting said first incubated suspension with an anti-ZIKV antibody detecting-reagent to permit binding of the anti-ZIKV antibody detecting reagent to said microspheres, removing from the second incubated suspension anti-ZIKV antibody detecting-reagent molecules that are not bound to said microspheres, and detecting the presence of anti-ZIKV antibody detecting-reagent molecules in the second incubated suspension.Type: GrantFiled: June 10, 2019Date of Patent: November 30, 2021Assignees: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, HEALTH RESEARCH, INC.Inventors: Susan J. Wong, Pei-Yong Shi
-
Patent number: 10996216Abstract: The present invention relates to a method for applying a principle of Deterministic Lateral Displacement (DLD), and for separating cells depending on the particle sizes on the basis of the DLD principle after capturing targeted cells or untargeted cells on a carrier and thereby increasing particle sizes.Type: GrantFiled: February 26, 2016Date of Patent: May 4, 2021Assignee: TOPPAN PRINTING CO., LTD.Inventor: Noriaki Arai
-
Patent number: 10851410Abstract: The invention provides compositions and methods for sequencing nucleic acids and other applications. In sequencing by synthesis, unlabeled reversible terminators are incorporated by a polymerase in each cycle, then labeled after incorporation by binding to the reversible terminator a directly or indirectly labeled antibody or other affinity reagent.Type: GrantFiled: January 4, 2018Date of Patent: December 1, 2020Assignees: MGI Tech Co., Ltd., BGI ShenzhenInventors: Radoje Drmanac, Snezana Drmanac, Handong Li, Xun Xu, Matthew J. Callow, Leon Eckhardt, Naibo Yang
-
Patent number: 10598643Abstract: Disclosed is a method for detecting the presence of a type I pyrethroid in an object including the steps of (a) contacting the object with a solvent and an absorbent substrate, (b) separating the absorbent substrate from the object, (c) evaporating the solvent from the absorbent substrate, (d) treating the absorbent substrate with a solution comprising a nitrite salt in concentrated sulfuric acid, and (e) observing the absorbent substrate for a color change indicating the presence of the type I pyrethroid in the object. The invention also provides a kit for detecting the presence of the type I pyrethroid in an object.Type: GrantFiled: June 10, 2016Date of Patent: March 24, 2020Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventor: Michael D. Green
-
Patent number: 10323091Abstract: The instant disclosure provides antibodies that specifically bind to human PD-1 and antagonize PD-1 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.Type: GrantFiled: September 1, 2016Date of Patent: June 18, 2019Assignees: Agenus Inc., Memorial Sloan Kettering Cancer Center, Ludwig Institute for Cancer Research LtdInventors: Marc van Dijk, Nicholas Stuart Wilson, Cornelia Anne Mundt, Gerd Ritter, Jedd David Wolchok, Taha Merghoub, Roberta Zappasodi, Rikke Bæk Holmgaard, David Schaer, David Adam Savitsky
-
Patent number: 10209248Abstract: The present invention provides an immunoassay leading to the rapid and simultaneous detection of antibodies to a wide range of infectious pathogens in biological fluids of infected patients. This immunoassay involves the covalent and oriented coupling of fusion proteins comprising an AGT enzyme and a viral antigen on an identifiable solid support (e.g. fluorescent microspheres). The thus obtained antigen-coupled microspheres show enhanced capture of specific antibodies as compared to antigen-coupled microspheres produced by standard amine coupling procedures.Type: GrantFiled: July 19, 2017Date of Patent: February 19, 2019Assignee: Institut PasteurInventors: Jean-Claude Manuguerra, Jessica Vanhomwegen, Philippe Despres, Sylvie Paulous
-
Patent number: 9512212Abstract: The present invention relates to therapeutic agents comprising bispecific recombinant antibody fragments to selectively clear a protein associated with a neurological disease and methods of use of these therapeutic agents to treat neurological diseases.Type: GrantFiled: January 10, 2013Date of Patent: December 6, 2016Assignee: Arizona Board of Regents, a Body Corporate of the State of Arizona, Acting for and on Behalf of Arizona State UniversityInventors: Michael Sierks, Yong Shen
-
Patent number: 9458246Abstract: Described herein are bispecific proteins specific for BAFF and B7RP1, nucleic acids encoding such proteins, methods of making such proteins, and uses for such proteins.Type: GrantFiled: March 10, 2014Date of Patent: October 4, 2016Assignee: AMGEN INC.Inventors: Hailing Hsu, Ming Zhang, Gunasekaran Kannan, Frederick W. Jacobsen, Wayne Tsuji
-
Patent number: 9169330Abstract: The present invention relates to a hybridoma producing an anti-methylated DNA antibody, obtained by cell fusion of an antibody-producing cell obtained from an animal immunized with an antigen containing 5?-(5-methyl-2?-deoxycytidine-3?-phospho)-2?-deoxyguanosine 3?-phosphate with a myeloma cell. The present invention also relates to a monoclonal antibody produced by the hybridoma and a method for immunoprecipitation of a methylated DNA using the antibody.Type: GrantFiled: March 26, 2012Date of Patent: October 27, 2015Assignee: SYSMEX CORPORATIONInventors: Ayako Sakai, Masahiro Kajita
-
Publication number: 20150072368Abstract: Novel transcription units that may be used in expression vectors. The transcription unit allow antibodies to be produced whose gain in productivity is not linked to a particular antigenic target antibody and therefore by extrapolation to a given recombinant protein, nor linked to the culture medium.Type: ApplicationFiled: February 8, 2013Publication date: March 12, 2015Applicant: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIESInventors: Alexandre Fontayne, François Coutard
-
Publication number: 20150044236Abstract: Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.Type: ApplicationFiled: May 22, 2014Publication date: February 12, 2015Applicant: AMGEN INC.Inventors: Kenneth W. WALKER, Yue-Sheng LI, Thomas Charles BOONE, HoSung MIN, Jane TALVENHEIMO, Taruna ARORA, Frederick W. JACOBSEN
-
Publication number: 20150044235Abstract: Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.Type: ApplicationFiled: May 22, 2014Publication date: February 12, 2015Applicant: Amgen Inc.Inventors: Kenneth W. WALKER, Yue-Sheng LI, Thomas Charles BOONE, George DOELLGAST (DECEASED), HoSung MIN, Jane TALVENHEIMO, Taruna ARORA, Frederick W. JACOBSEN
-
Patent number: 8946167Abstract: The invention is related to water-soluble products and pharmaceutical formulations in solid or liquid form mainly for parenteral use. They consist of or comprise a therapeutically active substance (having low aqueous solubility and a substantial binding affinity to plasma proteins) and a plasma protein fraction in controlled aggregation state, whereby the said active substance and the said protein fraction are bound to each other by way of non-covalent bonds. It also covers processes for the preparation of the product and pharmaceutical formulation by dissolving the water-insoluble active substance in a water-miscible, pharmaceutically acceptable solvent, combining said solution with the aqueous solution of a plasma protein fraction in controlled aggregation state whereby a true solution is obtained containing the said active substance and the said protein fraction bound together by way of non-covalent bonds.Type: GrantFiled: February 9, 2009Date of Patent: February 3, 2015Assignee: Teva Pharmaceutical Industries Ltd.Inventors: Lajos Hegedus, Krisztina Krempels, Krisztina Paal, Gabor Petho
-
Publication number: 20140349319Abstract: The present invention provides a method of detecting or measuring trans-Resveratrol (tRV) in a sample, comprising: contacting a sample to be tested with an antibody against tRV, or an antigen binding fragment of such an antibody; and detecting or measuring any tRV bound by the antibody or antibody fragment. The invention also provides an antibody against trans-Resveratrol.Type: ApplicationFiled: November 9, 2012Publication date: November 27, 2014Inventors: Ivan Petyaev, Valery Tsybezov
-
Publication number: 20140336156Abstract: Provided herein are antigenic molecules that can be used to generate antibodies capable of binding to a vitamin D derivative, such as 25-hydroxyvitamin D2 and/or 25-hydroxyvitamin D3, or a 25-hydroxyvitamin D analog, such as a vitamin D-C22 immunogenic molecule or compound. Antibodies produced using these antigenic molecules, and related antigenic compounds, are also described. In addition, disclosed herein are methods for detecting vitamin D deficiency in a subject, methods for treating a subject suspected of having a vitamin D deficiency, methods for monitoring progression of vitamin D deficiency in a subject, and methods for monitoring treatment of vitamin D deficiency in a subject in need thereof. The methods involve the detection or quantification of 25-hydroxyvitamin D2 and D3.Type: ApplicationFiled: July 18, 2014Publication date: November 13, 2014Inventors: NIVER PANOSIAN SAHAKIAN, Bruce A. Campbell, Spencer Hsiang-Hsi Lin, JAMES Vincent FREEMAN, Qimu Liao, RAMON A. EVANGELISTA
-
Publication number: 20140314832Abstract: The present invention relates to pharmaceutical and medical technologies, and more particularly to novel nanobodies against pulmonary surfactant protein A (SP-A) and their preparation methods. The nanobodies of the present invention comprises an amino acid sequence having certain formula. The present invention also relates to nucleic acid sequences encoding the nanobodies, their preparation method and their applications. Immunohistochemistry and in vivo imaging show that the nanobodies of the present inventions have high lung-targeting specificity.Type: ApplicationFiled: August 2, 2013Publication date: October 23, 2014Applicant: Shanghai Pulmonary Hospital, Tongji University School of MedicineInventors: Huiping Li, Shanmei Wang
-
Patent number: 8846391Abstract: The invention provides methods for sensitive and specific detection of anti-HSV-2 antibodies by depletion of cross-reactive (non-specific) antibodies in a biological sample that can lead to a false positive result. The invention also features compositions, including nucleic acids, polypeptides, and kits, for use in the methods of the invention.Type: GrantFiled: June 23, 2010Date of Patent: September 30, 2014Assignee: Focus Diagnostics, Inc.Inventors: Xin Su, Lilly Kong, Wayne Hogrefe
-
Publication number: 20140271688Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: ApplicationFiled: March 12, 2014Publication date: September 18, 2014Applicants: IRM LLC, NOVARTIS AGInventors: Tinya Abrams, Steven Bruce Cohen, Christie P. Fanton, Thomas Huber, Kathy Miller, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette, Catrin Finner
-
Publication number: 20140193413Abstract: The present disclosure relates to an antibody or antibody fragment capable of binding to phosphorylcholine and/or a phosphorylcholine conjugate, wherein the antibody or antibody fragment comprises a variable heavy chain (VH) domain and/or a variable light chain (VL) domain, and wherein (a) the VH domain comprises complementarity determining regions (CDRs) selected from the group consisting of: a CDR1 sequence having identity to the sequence of SEQ ID NO: 7; a CDR2 sequence having identity to the sequence of SEQ ID NO: 8; and a CDR3 sequence having identity to the sequence of SEQ ID NO: 9 or 10; and/or (b) the VL domain comprises CDRs selected from the group consisting of: a CDR4 sequence having identity to the sequence of SEQ ID NO: 11; a CDR5 sequence having identity to the sequence of SEQ ID NO: 12; a CDR6 sequence having identity to the sequence of SEQ ID NO: 13.Type: ApplicationFiled: August 8, 2012Publication date: July 10, 2014Applicants: DYAX CORP., ATHERA BIOTECHNOLOGIES ABInventors: Knut Pettersson, Ola Camber, Dan Sexton, Andrew E. Nixon
-
Publication number: 20140186377Abstract: The present invention encompasses prostaglandin E2 (PGE2) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin E2 and neutralize prostaglandin E2 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody, or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting prostaglandin E2 and for inhibiting prostaglandin E2 activity, e.g., in a human subject suffering from a disorder in which prostaglandin E2 activity is detrimental.Type: ApplicationFiled: November 26, 2013Publication date: July 3, 2014Applicant: AbbVie, Inc.Inventors: Jijie Gu, Charles W. Hutchins, Rong-Rong Zhu, Jianwei Shen, Maria C. Harris, Eileen Belanger, Tariq Ghayur, Paul R. Hinton, Veronica M. Juan, John Mankovich, Junjian Liu
-
Publication number: 20140178410Abstract: The present invention relates to an antibody or antibody fragment capable of binding to phosphorylcholine and/or a phosphorylcholine conjugate, wherein the antibody or antibody fragment comprises a variable heavy chain (VH) domain and/or a variable light chain (VL) domain, and wherein—(a) the VH domain comprises an amino acid sequence that includes one, two or three complementarity determining regions (CDRs) selected from the group consisting of: a CDR1 sequence comprising an amino acid sequence having at least 25%, 50%, 75% or 100% sequence identity to the sequence of SEQ ID NO: 17; a CDR2 sequence comprising an amino acid sequence having at least 5%, 11%, 17%, 23%, 29%, 35%, 47%, 52%, 58%, 64%, 70%, 76%, 82%, 94% or 100% sequence identity to the sequence of SEQ ID NO: 18; and a CDR3 sequence comprising an amino acid sequence having at least 4%, 9%, 13%, 18%, 22%, 27%, 31%, 36%, 40%, 45%, 50%, 54%, 59%, 63%, 68%, 72%, 77%, 81%, 86%, 90%, 95% or 100% sequence identity to the sequence of SEQ ID NO: 19, 20, 21Type: ApplicationFiled: August 8, 2012Publication date: June 26, 2014Applicants: DYAX CORP., ATHERA BIOTECHNOLOGIES ABInventors: Knut Pettersson, Ola Camber, Dan Sexton, Andrew E. Nixon
-
Publication number: 20140093915Abstract: Provided herein are IL-18 receptor antigen binding proteins and polynucleotides encoding the same. Expression vectors and host cells comprising the same for production of the antigen binding proteins are also provided. In addition, provided are compositions and methods for diagnosing and treating diseases mediated by IL-18 receptor.Type: ApplicationFiled: September 3, 2013Publication date: April 3, 2014Applicant: AMGEN INC.Inventors: DIRK E. SMITH, JOHN E. SIMS, JEFFREY T. MCGREW, MAREK Z. KUBIN, DUNCAN COCHRANE, LOUISE CONROY
-
Publication number: 20140050743Abstract: The present invention relates to the identification and use of antigen-binding regions, antibodies, antigen-binding antibody fragments and antibody mimetics, neutralizing the anti-coagulant effect of an anticoagulant in vitro and/or in vivo. Antibodies and functional fragments of the invention and antibody mimetics can be used to specifically reverse the pharmacological effect of an anticoagulant e.g. a FXa inhibitor for therapeutic (antidote) and/or diagnostic purposes. The invention also provides nucleic acid sequences encoding foregoing molecules, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: ApplicationFiled: January 17, 2012Publication date: February 20, 2014Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Frank Dittmer, Anja Buchmüller, Christoph Gerdes, Adrian Tersteegen, Mark Jean Gnoth, Lars Linden, Axel Harrenga, Joanna Grudzinska-Goebel, Mario Jeske, Martina Schäfer, Jörg Birkenfeld, Holger Paulsen, Ricarda Finnern, Anke Mayer-Bartschmid, Andrea Eicker, Simone Greven, Susanne Steinig
-
Publication number: 20140044739Abstract: The present disclosure relates to Cell Death Inducing Molecule (“CDIM”) binding proteins and pharmaceutical compositions thereof. Particularly, the disclosure provides CDIM binding proteins that are useful in the selective depleting and killing of B cells, including neoplastic B cells as well as neoplastic cells that are not of B-cell origin that express CDIM-like antigens. In addition, the disclosure encompasses polynucleotides encoding the disclosed antigen binding proteins, and expression systems for producing the same. Further the present disclosure encompasses methods of treating patients with B cell proliferative- and mediated diseases by administering the CDIM binding proteins as well as diagnostic assays for identifying proteins that bind to CDIM. The disclosure further contemplates diagnostic assays for identifying patient populations that can be treated with the CDIM binding proteins.Type: ApplicationFiled: February 8, 2013Publication date: February 13, 2014Inventors: Nelson N. H. Teng, Neelima M. Bhat, Marcia M. Bieber, Bruce A. Keyt
-
Publication number: 20140030271Abstract: The present invention concerns monoclonal antibodies specifically binding the human HMGB1 protein and further HMGB1 proteins of mammalian origin and also concerns fragments thereof, nucleic acids encoding such antibodies or fragments thereof, as well as vectors, cells, and compositions comprising the antibodies or nucleic acids, and uses thereof.Type: ApplicationFiled: April 5, 2011Publication date: January 30, 2014Applicant: DIA.PRO DIAGNOSTIC BIOPROBES S.R.L.Inventor: Cristina Scozzesi
-
Publication number: 20130317201Abstract: It is an object of the present invention to provide an anti-cadherin antibody having a high internalization capacity and provide an anti-cadherin antibody-drug conjugate that effectively kills cadherin-expressing cancer cells with the use of such antibody. The present invention provides an anti-cadherin antibody which recognizes a cadherin domain 1 (EC1) of cadherin and exhibits a high internalization capacity.Type: ApplicationFiled: October 28, 2011Publication date: November 28, 2013Applicant: PERSEUS PROTEOMICS INC.Inventors: Keisuke Ishii, Keiko Katsumi, Tadashi Matsuura, Yukio Sudo, Katsuyuki Mitomo, Katsushi Kouda
-
Publication number: 20130295095Abstract: The invention relates to binding molecules capable of specifically recognizing soluble oligomers of N-terminal truncated A? starting with pyroglutamate (A??E), pharmaceutical compositions comprising same, and their respective therapeutic uses. Particularly, the invention relates to an antibody molecule capable of specifically recognizing A? oligomers, wherein said antibody binds and/or detects an epitope as bound and/or detected by antibody PG3-38 9D5H6 as deposited under DSM AC-C3056.Type: ApplicationFiled: June 3, 2011Publication date: November 7, 2013Inventors: Thomas Bayer, Oliver Wirths, Henrik Martens, Christian Erck
-
Publication number: 20130287799Abstract: The subject invention relates to monoclonal antibodies that may be used in the treatment and diagnosis of Alzheimer's Disease. In particular, the present invention relates to monoclonal antibodies referred to as 10F4 and 3C5 and to other monoclonal antibodies (e.g., murine, human or humanized) having similar properties thereto.Type: ApplicationFiled: April 15, 2013Publication date: October 31, 2013Inventors: Abbott Laboratories, Abbott GmbH & Co. KG
-
Patent number: 8507214Abstract: The present invention provides an ELISA kit for detecting lincomycin comprising a coating antigen and an enzyme labeled reagent, wherein the coating antigen is selected from the group consisting of a lincomycin hapten-carrier protein conjugate, a lincomycin antibody and a lincomycin anti-antibody; when the coating antigen is the lincomycin hapten-carrier protein conjugate, the enzyme labeled reagent is an enzyme-labeled lincomycin anti-antibody; when the coating antigen is the lincomycin antibody, the enzyme labeled reagent is an enzyme-labeled lincomycin hapten-carrier protein conjugate; and when the coating antigen is the lincomycin anti-antibody, the enzyme labeled reagent is an enzyme-labeled lincomycin hapten-carrier protein conjugate; and the lincomycin hapten is obtained through the condensation reaction between lincomycin and succinic anhydride.Type: GrantFiled: September 27, 2008Date of Patent: August 13, 2013Assignee: Beijing Kwinbon Biotechnology Co., Ltd.Inventors: Fangyang He, Yuping Wan, Caiwei Feng, Zhengmiao Zhao, Caimao Feng, Shanliang Wang, Xiaoqin Luo, Xiaobin Ma
-
Publication number: 20130195872Abstract: This invention provides fully human monoclonal antibodies that recognize IL-17F, the IL-17F homodimer, IL-17A, the IL-17A homodimer, and/or the heterodimeric IL-17A/IL-17F protein complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.Type: ApplicationFiled: March 14, 2013Publication date: August 1, 2013Applicant: NOVIMMUNE S.A.Inventor: NOVIMMUNE S.A.
-
Publication number: 20130189283Abstract: Disclosed is an isolated immunoglobulin. Also disclosed are pharmaceutical compositions and medicaments comprising the immunoglobulin, isolated nucleic acid encoding it, vectors, host cells, useful in methods of making it. In some embodiments the immunoglobulin comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.Type: ApplicationFiled: September 22, 2011Publication date: July 25, 2013Applicant: AMGEN INC.Inventors: Kenneth W. Walker, Frederick W. Jacobsen, Taruna Arora
-
Patent number: 8491907Abstract: The invention described herein provides for human antibodies produced in non-human animals that specifically bind to lipopolysaccharide (LPS) from strains Fisher Devlin (International Serogroups) It-2 (011), It-3 (02), It-4 (01), It-5 (010), It-6 (07), PA01 (05), 170003 (02), IATS016 (02/05), and 170006 (02). The invention further provides methods for making the antibodies in a non-human animal, expression of the antibodies in cell lines including hybridomas and recombinant host cell systems. Also provided are kits and pharmaceutical compositions comprising the antibodies and methods of treating or preventing pseudomonas infection by administering to a patient the pharmaceutical compositions described herein.Type: GrantFiled: July 13, 2010Date of Patent: July 23, 2013Assignee: Amgen, Inc.Inventor: John R. Schreiber
-
Patent number: 8435784Abstract: A method of preserving haptenized tumor cells is described. The method employs a freezing medium containing an effective amount of sucrose and human serum albumin in an isotonic buffered saline solution. Cryogenically preserving haptenized cells in such a medium has been found to maintain the integrity of the tumor cells during storage. The haptenized tumor cells also retain cell-associated antigens and haptens, and are as immunogenic, i.e., capable of inducing immunotherapeutic response, as fresh vaccine in a mouse model of metastatic disease. In a specific embodiment, haptenized cells are exposed to a solution of 8% sucrose, 10% human serum albumin in Hank's buffered solution, and then frozen to ?80° C. overnight and then stored in a liquid nitrogen freezer. Methods of storing haptenized tumor cells and compositions are also provided.Type: GrantFiled: June 13, 2007Date of Patent: May 7, 2013Inventors: David Berd, Lorne F. Erdile, Margalit B. Mokyr
-
Publication number: 20130108644Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.Type: ApplicationFiled: August 27, 2012Publication date: May 2, 2013Inventors: Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Fuh, Yu Miao
-
Publication number: 20130059825Abstract: Provided herein are antigenic molecules that can be used to generate antibodies capable of binding to a vitamin D derivative, such as 25-hydroxyvitamin D2 and/or 25-hydroxyvitamin D3, or a 25-hydroxyvitamin D analog, such as a vitamin D-C22 immunogenic molecule or compound. Antibodies produced using these antigenic molecules, and related antigenic compounds, are also described. In addition, disclosed herein are methods for detecting vitamin D deficiency in a subject, methods for treating a subject suspected of having a vitamin D deficiency, methods for monitoring progression of vitamin D deficiency in a subject, and methods for monitoring treatment of vitamin D deficiency in a subject in need thereof. Also provided are methods and reagents for the detection or quantification of 25-hydroxyvitamin D2 and D3, methods for stabilizing vitamin D analogs, and methods for separating 25-hydroxyvitamin D2 and D3 from vitamin D binding protein in a biological sample.Type: ApplicationFiled: April 27, 2012Publication date: March 7, 2013Applicant: Siemens Healthcare Diagnostics Inc.Inventors: Niver Panosian Sahakian, Bruce A. Campbell, Spencer Hsiang-Hsi Lin, James Vincent Freeman, Qimu Liao, Ramon A. Evangelista
-
Publication number: 20120100158Abstract: A hybridoma cell which has been deposited under ATCC Accession Number PTA-9974 is disclosed. Also provided are Antibodies and methods of using same.Type: ApplicationFiled: April 29, 2010Publication date: April 26, 2012Applicant: RAMOT AT TEL AVIV UNIVERSITY LTD.Inventors: Gal Markel, Rona Ortenberg
-
Patent number: 8153767Abstract: It is intended to detect, concentrate and purify aflatoxins of all types which are possibly contained in a sample such as a food. It is also intended to detect the total amount or the individual amounts thereof at a high sensitivity. By using aflatoxin B2 or its derivative as a hapten compound, an antibody, which shows the same reactivity to individual aflatoxin analogs and is highly tolerant to organic solvents, is obtained. Then, a detection/concentration/purification means and an immunological detection means with the use of the above antibody are constructed. The detection means thus constructed achieves a high sensitivity and excellent quantification properties.Type: GrantFiled: November 13, 2007Date of Patent: April 10, 2012Assignee: HORIBA, Ltd.Inventors: Mikiko Uchigashima, Shiro Miyake, Hiroshi Yamashita
-
Patent number: 8148059Abstract: A method of detecting malignancy of nasopharyngeal carcinoma and a nasopharyngeal carcinoma malignancy biomarker are disclosed. Firstly, a specimen is obtained from a testee. Next, the specimen is tested for its MIP-3? expression level. Then, the MIP-3? expression level of the specimen is compared with that of a control. Finally, the malignancy of nasopharyngeal carcinoma is determined according to a relative MIP-3? expression level between the specimen and the control.Type: GrantFiled: October 30, 2009Date of Patent: April 3, 2012Assignee: Chang Gung UniversityInventors: Jau-Song Yu, Kai-Ping Chang
-
Publication number: 20120045443Abstract: The invention concerns agonist anti-trkC monoclonal antibodies which mimic certain biological activities of NT-3, the native ligand of trkC. The invention further concerns the use of such antibodies in the prevention and/or treatment of cellular degeneration, including nerve cell damage associated with acute nervous cell system injury and chronic neurodegenerative diseases, including peripheral neuropathy.Type: ApplicationFiled: August 5, 2011Publication date: February 23, 2012Inventors: Brigitte Devaux, Jo-Anne Hongo, Leonard G. Presta, David L. Shelton
-
Publication number: 20120027782Abstract: The present disclosure relates to antibody-partner molecule conjugates directed to PTK7. Also described are methods for treating or preventing a disease characterized by growth of tumor cells expressing PTK7 using the antibody-partner molecule conjugates.Type: ApplicationFiled: November 26, 2008Publication date: February 2, 2012Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: Jonathan Alexander Terrett, Chin Pan, Chetana Rao-Naik
-
Publication number: 20120015380Abstract: In this invention, anti-PEG antibodies or anti-methoxyl-PEG (anti-CH3O-PEG) antibodies were expressed on cell surface which can collocate with a biotinylated anti-PEG antibody (AGP4-Biotin) or biotinylated PEG (PEG-Biotin) to develop a cell-based sandwich ELISA or a cell-based competition ELISA, respectively. Both of these two methods could sensitively quantify free PEG and PEG-modified macromolecules (proteins, nanoparticles and liposomes) as sensitive as nano-gram level.Type: ApplicationFiled: February 22, 2011Publication date: January 19, 2012Applicant: KAOHSIUNG MEDICAL UNIVERSITYInventors: Tian-Lu Cheng, Steven R. Roffler, Kuo-Hsiang Chuang, Ssu-Jung Lu
-
Publication number: 20110305715Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to 3-hydroxycotinine (3HC). The invention also provides compositions containing these antibodies and fragments thereof, and to their use in diagnostic and therapeutic applications for diseases involving nicotine activity (e.g., smoking and/or smokeless tobacco use).Type: ApplicationFiled: June 10, 2011Publication date: December 15, 2011Inventors: Lynn Y. Miao, Jennifer G. Johnson, Adriana Navarro, Paul Olivo, David Scholl
-
Publication number: 20110280884Abstract: A human antibody or a functional fragment thereof having specific binding ability to CD98 which is derived from the cell membrane of cancer cells and is in the form of a complex with a protein having an amino acid transporter activity (for example, LAT1) is disclosed. This antibody binds to CD98 in the form of a dimer with LAT1 on the surface of cancer cells, specifically attacks cancer cells expressing CD98 via the immune system by ADCC or CDC, and further inhibits amino acid uptake of the cancer cells via LAT1, to suppress growth of the cancer cells. Accordingly, a preventive and therapeutic agent for cancer comprising this antibody or a fragment thereof, which acts on various cancers, is specific to cancer, and causes no side effect, is provided.Type: ApplicationFiled: May 12, 2011Publication date: November 17, 2011Inventors: Tomoyuki TAHARA, Yoshikatsu Kanai, Hitoshi Endou, Shiro Kataoka, Kazumasa Hasegawa, Tetsuya Yoshino
-
Patent number: 8048676Abstract: The invention provides reagents and methods for detecting pathogen infections in human samples. This detection utilizes specific proteins to detect the presence of pathogen proteins or abnormal expression of human proteins resulting from pathogen infections. Specific methods, compositions and kits are disclosed herein for the detection of oncogenic Human papillomavirus E6 proteins in clinical samples.Type: GrantFiled: January 5, 2007Date of Patent: November 1, 2011Assignee: Arbor Vita CorporationInventors: Peter S. Lu, Johannes Schweizer, Chamorro Somoza Diaz-Sarmiento, Michael P. Belmares
-
Patent number: 8039599Abstract: Monoclonal antibodies to rapamycin and to 40-O-alkylated derivatives of rapamycin are provided, together with novel haptens, immunogenic conjugates, and processes for making them and assay kits for using them.Type: GrantFiled: June 2, 2000Date of Patent: October 18, 2011Assignee: Novartis AGInventors: Richard Sedrani, Valerie Quesniaux
-
Patent number: 8021849Abstract: Methods and kits for determining sirolimus in a sample known or suspected to contain sirolimus are provided. The methods and kits according to the invention use one or more antibodies generated using a fragment of sirolimus, such as the northern fragment of sirolimus.Type: GrantFiled: November 5, 2004Date of Patent: September 20, 2011Assignee: Siemens Healthcare Diagnostics Inc.Inventor: Michael S. Huster
-
Publication number: 20110223684Abstract: Methods are described for improving the diagnostic possibilities of diseases where oxidative NO-modifications occur, for example inflammatory conditions, cancer, Parkinson's or Alzheimer's disease, and to provide means of monitoring the effects of therapeutical measures taken towards such diseases. The invention enables the detection of disease specific catabolic markers related to oxidative NO-modifications, utilizing an immunoassay comprising antibodies directed against nitrated and non-nitrated epitopes characteristic of a specific protein.Type: ApplicationFiled: January 20, 2011Publication date: September 15, 2011Inventors: Jean-Yves Reginster, Michelle Deberg, Yves Henrotin, Stephan Christgau
-
Patent number: 8008001Abstract: The present invention relates to a vaccine and a method for protecting piglets against PCV-2 infection by administering a vaccine comprising at least 20 micrograms/dose of ORF-2 protein of porcine circovirus type 2, even when they have a relatively high titer of maternally derived antibodies against PCV-2. A vaccine according to the invention may contain a recombinant ORF-2 protein, wherein said recombinant protein is preferably produced by way of expression from a baculovirus expression vector in insect cells, said baculovirus expression vector containing the PCV-2 ORF-2 gene sequence under control of a suitable promoter.Type: GrantFiled: December 11, 2009Date of Patent: August 30, 2011Assignee: Intervet International B.V.Inventors: Frank Roerink, Peter Van Woensel
-
Patent number: 7943343Abstract: The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a targetable conjugate. The targetable conjugate encompasses a hapten to which antibodies have been prepared. In preferred embodiments, the hapten is histamine-succinyl-glycine (HSG). In more preferred embodiments, the at least one arm comprises the CDR sequences of the HSG-binding 679 antibody. The targetable conjugate is attached to one or more therapeutic and/or diagnostic agents. The invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them and kits comprising them.Type: GrantFiled: October 20, 2009Date of Patent: May 17, 2011Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, Gary L. Griffiths, Shui-on Leung, William J. McBride, Zhengxing Qu
-
Patent number: 7910310Abstract: This invention relates to the relationship between infection with an adipogenic adenovirus, such as adenovirus-36, and obesity-related disease. In particular, this invention relates to assaying a subject to determine the adipogenic adenovirus infection status and then determining the subject's predisposition to developing an obesity-related disease based on the adipogenic adenovirus infection status.Type: GrantFiled: October 24, 2008Date of Patent: March 22, 2011Assignee: Obetech, LLCInventor: Richard L. Atkinson